Esomeprazole: In Gastroesophageal Reflux Disease in Children and Adolescents

Authors: Croxtall, Jamie D.; Perry, Caroline M.; Keating, Gillian M.

Source: Pediatric Drugs, Volume 10, Number 3, 2008 , pp. 199-205(7)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

▴ Esomeprazole is the S-isomer of the proton pump inhibitor omeprazole and, administered orally, has been evaluated in the management of gastroesophageal reflux disease (GERD) in children aged 1-11 years and adolescents aged 12-17 years. Further studies in children are ongoing.

▴ In an 8-week, randomized, double-blind, multicenter trial, a significant improvement from baseline in parent-rated GERD symptom scores was seen in children with endoscopically proven GERD aged 1-11 years stratified to receive oral esomeprazole 5 or 10 mg (in those weighing <20 kg) or 10 or 20 mg (in those weighing ≥20 kg) once daily. A substudy demonstrated improved or healed erosive esophagitis in the majority of children following esomeprazole therapy.

▴ A significant improvement from baseline in parent- or patient-rated GERD-related symptom scores was observed in adolescents aged 12-17 years with clinically diagnosed GERD who received oral esomeprazole 20 or 40 mg once daily for 8 weeks in a randomized, double-blind, multicenter trial.

▴ Esomeprazole was generally well tolerated in children aged 1-11 years and adolescents aged 12-17 years with GERD, according to the results of well designed, short-term trials.

Keywords: Adis Drug Profiles; Adolescents; Children; Esomeprazole; Gastro oesophageal reflux

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2008-01-01